Stay updated on Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page.

Latest updates to the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now displays the Effisayil™ ON study record for long-term spesolimab treatment in people with generalized pustular psoriasis, including study design, eligibility, outcome measures, and participating locations. The study is listed as active but not recruiting.SummaryDifference65%

- Check19 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.2 to v3.8.0; the study record remains unavailable on the error page.SummaryDifference0.2%

- Check26 days agoChange DetectedA sitewide banner announces an NIH transition update, including a notice about using “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision number changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check61 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the previous detailed content. The detailed study information and related navigation are effectively hidden behind an access-block page.SummaryDifference16%

Stay in the know with updates to Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page.